Eli Lilly said its once-daily weight loss pill was effective for people with obesity and type 2 diabetes in a key trial, clearing the way for the drugmaker to seek regulatory approval across the globe.
The medicine, called orforglipron, belongs to a class of lucrative weight loss drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which also include Novo Nordisk’s Ozempic and Wegovy and Lilly’s Mounjaro.
